KARD
NASD Kardigan, Inc.$15.18 ↑ +0.93 (+6.49%) Trading Up from the previous close of $14.25, $0.09 below the day’s high of $15.27
- YTD change
- -31.02%
- vs 20-day SMA
- -11.57%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
-7.75 (-35.23%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 43.8% away from all-time highs of $27.00
- KARD is down 31% since the beginning of the year
- KARD is down 31% over the past 12 months
- KARD is down 31% over the past 1 month
- 4% of all KARD investors are betting against KARD
KARD reads not so good: the 12-month move is -35.2%.
- Previous minute
- +$0.01
- Last hour
- +$0.16
- Last 5 days
- +5.46%
- vs 8-day SMA
- +2.38%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence†platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
